

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934

November 5, 2001

(Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact name of registrant as specified in its charter)

DELAWARE	1-11353	13-3757370
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215

(Address of principal executive offices)

336-229-1127

(Registrant's telephone number, including area code)

ITEM 9. Regulation FD Disclosure.

Laboratory Corporation of America -Registered Trademark-
Holdings (LabCorp -Registered Trademark-)(NYSE:LH) announced
that Thomas P. Mac Mahon, chairman and chief executive
officer, is scheduled to speak at the CIBC World Markets
12th Annual Health Care Conference in New York City, NY on
Tuesday, November 6 at 8:30 a.m. Eastern Time. The
presentation will be webcast live, with a rebroadcast
available for 90 days, and may be heard online at
www.labcorp.com.

At the conference, Mr. Mac Mahon will reiterate Company
guidance for 2001 and 2002, as filed in an 8K on October 22.
Mr. Mac Mahon will state, "For 2001, we expect revenue
growth of 13.5 percent, EBITDA margins of approximately 21
percent of sales and EPS growth of approximately 55 percent
compared to 2000. For 2002, we expect to increase overall
revenues by approximately 12 percent compared to 2001 and we
expect EPS growth, as calculated under existing accounting
rules, of approximately 33 percent compared to 2001. In
calculating earnings and EPS under the new accounting rules
regarding goodwill, we expect the non-amortization of
goodwill to have an impact of approximately \$26 million in
2002, resulting in an increase to EPS of approximately
\$0.36."

Each of the above forward-looking statements is subject to
change based on various important factors, including without
limitation, competitive actions in the marketplace and
adverse actions of governmental and other third-party
payors. Further information on potential factors that could
affect LabCorp's financial results is included in the
Company's Form 10-K for the year ended December 31, 2000 and
subsequent SEC filings.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Registrant)

By:/s/ BRADFORD T. SMITH

Bradford T. Smith
Executive Vice President
and Secretary

Date: November 5, 2001